A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6005515?pdf=render |
id |
doaj-7a9d2c9add4948819d2354dc1f1d0598 |
---|---|
record_format |
Article |
spelling |
doaj-7a9d2c9add4948819d2354dc1f1d05982020-11-25T01:25:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019926410.1371/journal.pone.0199264A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.Nicholas DompeChristiaan KlijnSara A WatsonKatherine LengJenna PortTrinna CuellarColin WatanabeBenjamin HaleyRichard NeveMarie EvangelistaDavid StokoeMutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective clinically. We therefore implemented a CRISPR screening approach to identify novel agents to sensitize KRAS mutant NSCLC cells to MEK inhibitor treatment. This approach identified multiple components of the canonical RAS/MAPK pathway consistent with previous studies. In addition, we identified MAPK7 as a novel, strong hit and validated this finding using multiple orthogonal approaches including knockdown and pharmacological inhibition. We show that MAPK7 inhibition attenuates the re-activation of MAPK signaling occurring following long-term MEK inhibition, thereby illustrating that MAPK7 mediates pathway reactivation in the face of MEK inhibition. Finally, genetic knockdown of MAPK7 combined with the MEK inhibitor cobimetinib in a mutant KRAS NSCLC xenograft model to mediate improved tumor growth inhibition. These data highlight that MAPK7 represents a promising target for combination treatment with MEK inhibition in KRAS mutant NSCLC.http://europepmc.org/articles/PMC6005515?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nicholas Dompe Christiaan Klijn Sara A Watson Katherine Leng Jenna Port Trinna Cuellar Colin Watanabe Benjamin Haley Richard Neve Marie Evangelista David Stokoe |
spellingShingle |
Nicholas Dompe Christiaan Klijn Sara A Watson Katherine Leng Jenna Port Trinna Cuellar Colin Watanabe Benjamin Haley Richard Neve Marie Evangelista David Stokoe A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. PLoS ONE |
author_facet |
Nicholas Dompe Christiaan Klijn Sara A Watson Katherine Leng Jenna Port Trinna Cuellar Colin Watanabe Benjamin Haley Richard Neve Marie Evangelista David Stokoe |
author_sort |
Nicholas Dompe |
title |
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
title_short |
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
title_full |
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
title_fullStr |
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
title_full_unstemmed |
A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. |
title_sort |
crispr screen identifies mapk7 as a target for combination with mek inhibition in kras mutant nsclc. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective clinically. We therefore implemented a CRISPR screening approach to identify novel agents to sensitize KRAS mutant NSCLC cells to MEK inhibitor treatment. This approach identified multiple components of the canonical RAS/MAPK pathway consistent with previous studies. In addition, we identified MAPK7 as a novel, strong hit and validated this finding using multiple orthogonal approaches including knockdown and pharmacological inhibition. We show that MAPK7 inhibition attenuates the re-activation of MAPK signaling occurring following long-term MEK inhibition, thereby illustrating that MAPK7 mediates pathway reactivation in the face of MEK inhibition. Finally, genetic knockdown of MAPK7 combined with the MEK inhibitor cobimetinib in a mutant KRAS NSCLC xenograft model to mediate improved tumor growth inhibition. These data highlight that MAPK7 represents a promising target for combination treatment with MEK inhibition in KRAS mutant NSCLC. |
url |
http://europepmc.org/articles/PMC6005515?pdf=render |
work_keys_str_mv |
AT nicholasdompe acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT christiaanklijn acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT saraawatson acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT katherineleng acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT jennaport acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT trinnacuellar acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT colinwatanabe acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT benjaminhaley acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT richardneve acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT marieevangelista acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT davidstokoe acrisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT nicholasdompe crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT christiaanklijn crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT saraawatson crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT katherineleng crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT jennaport crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT trinnacuellar crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT colinwatanabe crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT benjaminhaley crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT richardneve crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT marieevangelista crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc AT davidstokoe crisprscreenidentifiesmapk7asatargetforcombinationwithmekinhibitioninkrasmutantnsclc |
_version_ |
1725113545579823104 |